FDA Approves First ADC Drug for Ultra-Rare Blood Cancer BPDCN
The regulator granted approval for pivekimab sunirine (Decnupaz) for blastic plasmacytoid dendritic cell neoplasm. In newly diagnosed patients, the drug achieved complete remission in 69.7% of cases, becoming the first targeted therapy for this aggressive disease available for outpatient use.
$10.1 Billion Bet Pays Off: The Real Winners and Silent Costs Behind the FDA's First CD123 ADC Approval
[The Gist]: What's Really Happening
On May 27, 2026, the FDA approved AbbVie's pivekimab sunirine (Decnupaz) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The media will write: "first ADC for ultra-rare cancer," "complete remission in 69.7%." But I'll tell you what's really going on.
This is not just a drug approval. It's the first public return on the $10.1 billion deal AbbVie paid for ImmunoGen in 2023. ImmunoGen developed not only Decnupaz but also the technology platform for next-generation ADCs. When AbbVie bought ImmunoGen, Wall Street analysts called the price "crazy" — too expensive for a company with one approved drug. And now Decnupaz has hit the market.
The inside story they're not telling: Decnupaz's real value is not in BPDCN. This disease affects 500-1000 people per year in the US. The market is tiny. But Decnupaz is a proof of concept for the entire CD123-directed approach. The next target is acute myeloid leukemia (AML), where incidence is 50 times higher. And AML data is already being collected in the expanded cohorts of CADENZA. AbbVie isn't shouting about it, but AML is the real jackpot.
Timeline and Context
Decnupaz's path to approval took nearly 6 years:
- October 2020 — FDA grants Breakthrough Therapy designation for BPDCN.
- 2023 — AbbVie closes the ImmunoGen deal for $10.1 billion, acquiring rights to pivekimab sunirine.
- May 27, 2026 — FDA approves Decnupaz for BPDCN.
- Next step — Expected expansion of indication to AML, where studies are already in mid-stage.
What's important: CADENZA is a Phase 1/2, not Phase 3. The FDA approved the drug based solely on data from 84 patients, without a randomized controlled trial. This unprecedented trust speaks to two things: first, BPDCN is so rare that enrolling 200 patients for a Phase 3 is physically impossible; second, the need for new therapies was critical.
Who Wins and Who Loses
Winners:
- AbbVie — The company just turned $10.1 billion in investment into its first commercial product. Shares rose over 1% on the approval day. But the real profit will come with expansion into AML — a $2-3 billion annual market. Decnupaz is the anchor product around which AbbVie will build a portfolio of ADCs for hematology.
- Naveen Pemmaraju, MD Anderson — The lead investigator of the study, a leukemia professor at MD Anderson, will now become the most sought-after consultant in BPDCN. His name will be on every poster, every presentation. The next consulting deal with AbbVie could easily be $2-3 million per year.
- Patients with newly diagnosed BPDCN — 69.7% complete remissions is a game-changing number. Previously, these patients were offered AML-protocol chemotherapy with toxicity that older men (median age 60-70) often couldn't tolerate. Decnupaz can be started in an outpatient setting — no hospitalization, no IV drip.
Losers:
- Stemline Therapeutics (for tagraxofusp, Elzonris) — Tagraxofusp was the only approved drug for BPDCN before Decnupaz. But it has a fatal flaw: a black box warning for capillary leak syndrome, requiring hospitalization for the first cycle. Doctors hate such drugs — because of risks, because of bureaucracy. Decnupaz with its outpatient regimen is a direct hit to Elzonris.
- Manufacturers of intensive chemotherapy — Cytarabine, daunorubicin. Their commercial units are already seeing volume declines in BPDCN. And although this is a tiny market, the precedent is important: ADCs are displacing classic chemotherapy even in ultra-rare tumors.
- Young companies developing CD123 ADCs — Vincerx with VIP943, Byondis with BYON4413, Stemline with SL-101. The entry barrier just got higher. To get FDA approval, they will need to show not just non-inferiority to "historical control," but superiority to Decnupaz. And that's a whole different story.
What the Media Isn't Saying
First and most important: In the relapsed/refractory cohort, complete remission is only 15.7%. Median survival is 5.8 months. The drug doesn't save those whose disease returned after prior therapy. It gives them 6 months of life instead of 3-4, but that's not a breakthrough. 39.4% of newly diagnosed patients proceeded to stem cell transplant — the main goal of BPDCN therapy. But 60% did not. And we don't know why: toxicity? progression? patient refusal? No data.
Second — a non-obvious insight: Decnupaz carries an indolinobenzodiazepine pseudodimer payload. This is not a classic DNA alkylator. This payload alkylates DNA and induces single-strand breaks, not double-strand breaks. Why? Because double-strand breaks are a "nuclear bomb": the cell dies quickly, but healthy tissues also suffer. Single-strand breaks are more selective. But this selectivity comes at a cost: resistance. Cells with active single-strand break repair mechanisms (e.g., PARP overexpression) can survive. And in the relapsed cohort, where resistance reigns, this explains why the response dropped to 15.7%.
Third: FDA black box warning for hepatotoxicity, including veno-occlusive disease (VOD) of the liver. VOD is a rare but fatal complication treated only with defibrotide (Jazz Pharmaceuticals, price $30,000+ per course). There is no data yet on VOD frequency in CADENZA — the study wasn't large enough to assess it. In the post-marketing period, when thousands of patients receive Decnupaz, the numbers could be ugly. Inside scoop: VOD most often occurs after stem cell transplant. And 39.4% of patients in CADENZA went on to transplant. AbbVie may be deliberately not publishing data on how many of those 13 patients developed VOD.
Fourth — insider-level insight: The MD Anderson researcher, lead author of a 2026 publication on targeted therapies for BPDCN, writes plainly: "Tagraxofusp laid the foundation for targeted therapy." But tagraxofusp is a CD123 conjugate with diphtheria toxin. It causes capillary leak. Decnupaz is an ADC, not an immunotoxin. AbbVie won technologically, but the price of victory is $10.1 billion. Now every new CD123 drug will have to be compared to Decnupaz, and that comparison won't favor newcomers.
Forecast: Next 30 Days and 90 Days
Next 30 days (through end of June 2026):
- Full publication of CADENZA data in a peer-reviewed journal (likely Journal of Clinical Oncology or Blood). Details on subgroups: age, ECOG status, prior therapies. Analysts will dissect those tables line by line.
- NCCN will release updated guidelines, making Decnupaz the preferred regimen for newly diagnosed BPDCN. Tagraxofusp will be pushed to second line.
- AbbVie will announce pricing. I expect $35,000-45,000 per 21-day cycle. Full course until progression (median 9.7 months) — about $200,000-250,000.
Next 90 days (through end of August 2026):
- Updated AML data will be presented at some congress (possibly EHA in June 2026). If efficacy in AML is confirmed at even 20-25% complete remissions, AbbVie's market cap will rise 3-5%.
- The European Medicines Agency (EMA) will receive a marketing application for Decnupaz. EMA is traditionally slower than the FDA, so European approval no earlier than mid-2027.
- First real-world data will emerge from centers using Decnupaz off-label for other CD123-positive tumors — systemic mastocytosis, blast transformation in myeloproliferative neoplasms. This will create precedents for indication expansion.
Decnupaz sales forecast:
- 2026 (first 6 months) — $50-70 million.
- 2027 (full first year, BPDCN only) — $150-200 million.
- 2028-2029 (with AML approval and possibly other CD123-positive tumors) — $500 million to $1 billion.
$10.1 billion for ImmunoGen was not a purchase of one drug. It was a purchase of a next-generation ADC platform. Decnupaz is the first stone in the foundation. If AML works, AbbVie will recoup the deal in 3-4 years. If not, it remains an expensive story about an ultra-rare disease with a thousand patients a year. But the bets are placed, and AbbVie is doubling down. Watch their ADC pipeline in hematology — the next strike is coming.
— Editorial Team
